Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

To determine the frequency of hepatocellular cancer in corticosteroid-treated severe autoimmune chronic active hepatitis and to identify risk factors for its development, 124 patients who were selected by uniform criteria, treated comparably and followed systematically for 111 ± 6 months were evaluated. Hepatocellular cancer was diagnosed in three patients (2%) after 66, 99 and 174 months of observation, respectively. The incidence of hepatocellular cancer was 1 per 350 patient-years of follow-up. All three patients with hepatocellular cancer had cirrhosis for at least 5 years. The frequency of neoplasm in patients with cirrhosis of at least 5 years' duration was 7%. The incidence of hepatocellular cancer in these patients with cirrhosis was 1 per 182 patient-years of follow-up, and the probability of tumor was 29% after 13 years. Late elevation of the serum α-fetoprotein level was associated with the presence of neoplasm but normal levels did not exclude the diagnosis. We conclude that patients with corticosteroid-treated severe autoimmune chronic active hepatitis are at risk for hepatocellular cancer. This risk is greatest in patients with cirrhosis for at least 5 years. Such patients are candidates for cancer surveillance.

Original languageEnglish (US)
Pages (from-to)1679-1683
Number of pages5
JournalHepatology
Volume8
Issue number6
StatePublished - 1988

Fingerprint

Autoimmune Hepatitis
Chronic Hepatitis
Hepatocellular Carcinoma
Adrenal Cortex Hormones
Liver Neoplasms
Fibrosis
Neoplasms
Fetal Proteins
Incidence
Observation

ASJC Scopus subject areas

  • Hepatology

Cite this

Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. / Wang, Kenneth Ke Ning; Czaja, A. J.

In: Hepatology, Vol. 8, No. 6, 1988, p. 1679-1683.

Research output: Contribution to journalArticle

@article{608a7e269e4f4e7e86217330f4d456a4,
title = "Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis",
abstract = "To determine the frequency of hepatocellular cancer in corticosteroid-treated severe autoimmune chronic active hepatitis and to identify risk factors for its development, 124 patients who were selected by uniform criteria, treated comparably and followed systematically for 111 ± 6 months were evaluated. Hepatocellular cancer was diagnosed in three patients (2{\%}) after 66, 99 and 174 months of observation, respectively. The incidence of hepatocellular cancer was 1 per 350 patient-years of follow-up. All three patients with hepatocellular cancer had cirrhosis for at least 5 years. The frequency of neoplasm in patients with cirrhosis of at least 5 years' duration was 7{\%}. The incidence of hepatocellular cancer in these patients with cirrhosis was 1 per 182 patient-years of follow-up, and the probability of tumor was 29{\%} after 13 years. Late elevation of the serum α-fetoprotein level was associated with the presence of neoplasm but normal levels did not exclude the diagnosis. We conclude that patients with corticosteroid-treated severe autoimmune chronic active hepatitis are at risk for hepatocellular cancer. This risk is greatest in patients with cirrhosis for at least 5 years. Such patients are candidates for cancer surveillance.",
author = "Wang, {Kenneth Ke Ning} and Czaja, {A. J.}",
year = "1988",
language = "English (US)",
volume = "8",
pages = "1679--1683",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis

AU - Wang, Kenneth Ke Ning

AU - Czaja, A. J.

PY - 1988

Y1 - 1988

N2 - To determine the frequency of hepatocellular cancer in corticosteroid-treated severe autoimmune chronic active hepatitis and to identify risk factors for its development, 124 patients who were selected by uniform criteria, treated comparably and followed systematically for 111 ± 6 months were evaluated. Hepatocellular cancer was diagnosed in three patients (2%) after 66, 99 and 174 months of observation, respectively. The incidence of hepatocellular cancer was 1 per 350 patient-years of follow-up. All three patients with hepatocellular cancer had cirrhosis for at least 5 years. The frequency of neoplasm in patients with cirrhosis of at least 5 years' duration was 7%. The incidence of hepatocellular cancer in these patients with cirrhosis was 1 per 182 patient-years of follow-up, and the probability of tumor was 29% after 13 years. Late elevation of the serum α-fetoprotein level was associated with the presence of neoplasm but normal levels did not exclude the diagnosis. We conclude that patients with corticosteroid-treated severe autoimmune chronic active hepatitis are at risk for hepatocellular cancer. This risk is greatest in patients with cirrhosis for at least 5 years. Such patients are candidates for cancer surveillance.

AB - To determine the frequency of hepatocellular cancer in corticosteroid-treated severe autoimmune chronic active hepatitis and to identify risk factors for its development, 124 patients who were selected by uniform criteria, treated comparably and followed systematically for 111 ± 6 months were evaluated. Hepatocellular cancer was diagnosed in three patients (2%) after 66, 99 and 174 months of observation, respectively. The incidence of hepatocellular cancer was 1 per 350 patient-years of follow-up. All three patients with hepatocellular cancer had cirrhosis for at least 5 years. The frequency of neoplasm in patients with cirrhosis of at least 5 years' duration was 7%. The incidence of hepatocellular cancer in these patients with cirrhosis was 1 per 182 patient-years of follow-up, and the probability of tumor was 29% after 13 years. Late elevation of the serum α-fetoprotein level was associated with the presence of neoplasm but normal levels did not exclude the diagnosis. We conclude that patients with corticosteroid-treated severe autoimmune chronic active hepatitis are at risk for hepatocellular cancer. This risk is greatest in patients with cirrhosis for at least 5 years. Such patients are candidates for cancer surveillance.

UR - http://www.scopus.com/inward/record.url?scp=0024235279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024235279&partnerID=8YFLogxK

M3 - Article

C2 - 2461338

AN - SCOPUS:0024235279

VL - 8

SP - 1679

EP - 1683

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -